Trial Profile
A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Onalespib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 22 Sep 2023 Planned End Date changed from 7 Sep 2023 to 7 Sep 2024.
- 20 Sep 2022 Planned End Date changed from 7 Sep 2022 to 7 Sep 2023.
- 12 Feb 2021 Planned primary completion date changed from 31 Jan 2021 to 31 Dec 2021.